"Puruishunxiang" erhält mehrere Millionen Yuan in Serie-A-Finanzierung mit Fokus auf die Entwicklung von Produkten für minimalinvasive Operationsinstrumente | Exklusivbericht von 36Kr
36Kr learned that recently, minimally invasive surgical instrument supplier "Puruishunxiang" has completed a Series A financing of tens of millions of yuan. This round of financing was invested by Yizhuang Guotou, and Maibo Capital served as the financial advisor. The raised funds will be used for the company's product R & D innovation and market expansion.
It is reported that Zou Jianlong, the founder of Puruishunxiang, graduated from Central University of Finance and Economics and has rich work experience in the medical device field. Previously, the ultrasonic scalpel brand Anhe Jialier, which Zou Jianlong participated in building, was successfully acquired by Kangqiao Capital.
In terms of product layout strategy, Puruishunxiang mainly follows the path of combining imitation and innovation. While ensuring that the core indicators of its products are not inferior to imported products, it better meets the clinical usage habits of domestic doctors. Currently, based on five core technology platforms including trauma surgery, energy surgery, electronic endoscopy, high - value consumables, and CDMO, Puruishunxiang has built a product matrix including dozens of varieties such as super suction knives, radiofrequency plasma, ultrasonic scalpel systems, urological surgery series consumables, and endoscopic surgery systems, and has obtained more than 30 domestic and international medical device registration certificates.
Taking the neurosurgery field that the company is currently focusing on as an example, in China, the common types of peripheral nerve injuries include nerve severance or contusion, nerve entrapment, and diabetic peripheral neuropathy. Among them, there are more than 800,000 cases each year that require repair products for treatment due to nerve entrapment injuries alone. Conservatively estimated, the corresponding sales space in the terminal market exceeds 3 billion yuan.
In the field of energy surgery, currently, the aging society background and the increasing penetration rate of minimally invasive surgery provide the main growth drivers for the energy surgical instrument market. In addition, the implementation of the centralized procurement policy is also boosting the sales share of domestic brands. Against this background, the product matrix in the energy surgery field with platform - type and intelligent control capabilities may have more market competitive advantages.
"Based on this, we are building a full - platform energy surgery product line covering five fields including ultrasonic surgery, bone power, and radiofrequency plasma, and carrying out product R & D according to the clinical demand characteristics of each segmented track. For example, in terms of ultrasonic surgery, compared with foreign products, domestic ultrasonic surgical systems have gaps in cutting efficiency and cutting accuracy. We focus on solving this problem during product development." Puruishunxiang introduced.
In terms of innovative products, Puruishunxiang has developed a number of innovative consumable products for the urology field, such as disposable non - vascular lumen guidewires, flexible mirror sheaths, drainage kits, stents, etc. Compared with similar products on the market, they have certain cost advantages.
It is also learned that since Puruishunxiang launched commercialization in 2024, several innovative products have entered many top - tier tertiary hospitals in China for clinical use. In terms of channels, the company mainly relies on the academic resource platforms of the Chinese Medical Association and various foundations to cooperate with hospitals at all levels, and is committed to "creating a healthy academic promotion model through professional medical technology exchanges".
Investor's view:
Yizhuang Guotou said that Puruishunxiang's diverse technology platforms and product pipelines, as well as its outstanding performance in the process of domestic substitution, are highly consistent with Yizhuang Guotou's investment strategy. Through this investment, Yizhuang Guotou is expected to help Puruishunxiang further expand its production scale, improve its R & D capabilities, accelerate the innovation and development of domestic high - end minimally invasive surgical instruments, and promote the upgrading of the regional medical and health industry.